RapidAI vs ScreenPoint Transpara

RapidAI's first FDA record dates to 2013 and ScreenPoint's to 2018, and the two never compete for the same budget line. Rapid covers stroke with CT perfusion, ASPECTS and LVO, plus ICH on non-contrast CT, and adds aneurysm, aortic and pulmonary embolism modules. Rapid LVO is cleared as computer-assisted triage and notification software under 21 CFR 892.2080. A hospital with a thrombectomy-capable code-stroke pathway is the fit, under an enterprise license at hospital level.

ScreenPoint's Transpara reads 2D and 3D mammograms. It carries eight 510(k)s, the latest for version 2.1.0 in August 2026, and the vendor pitches it as a "second pair of eyes". ScreenPoint says Transpara was the AI in the Lund University MASAI randomized trial, which suits a screening program that double-reads mammograms.